Clinical Trial Update: A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)-China Extension [Phase 3]

View source ↗

Summary

Phase 3 trial update of gefapixant (MK-7264) in adults with chronic cough completed; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cough

Drugs mentioned

• Gefapixant (gefapixant)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Chronic Cough | Phase 3 | Status: COMPLETED | Results posted: 2023-10-02